NAGIOS: RODERIC FUNCIONANDO

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer

Repositori DSpace/Manakin

dc.contributor.author	Martín, Miguel	es_ES
dc.contributor.author	Makhson, Anatoly	es_ES
dc.contributor.author	Gligorov, Joseph	es_ES
dc.contributor.author	Lichinitser, Mikhail	es_ES
dc.contributor.author	Lluch Hernández, Ana	es_ES
dc.contributor.author	Semiglazov, Vladimir	es_ES
dc.contributor.author	Scotto, Nana	es_ES
dc.contributor.author	Mitchell, Lada	es_ES
dc.contributor.author	Tjulandin, Sergei	es_ES
dc.date.accessioned	2015-06-19T10:18:01Z
dc.date.available	2015-06-19T10:18:01Z
dc.date.issued	2012	es_ES
dc.identifier.citation	The Oncologist Vol. 17 Issue 4: pp. 469-475	es_ES
dc.identifier.uri	http://hdl.handle.net/10550/44551
dc.description.abstract	The first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for patients with human epidermal growth factor receptor-2–positive locally recurrent or metastatic breast cancer are reported.	es_ES
dc.subject	Bevacizumab	es_ES
dc.subject	Trastuzumab	es_ES
dc.subject	Capecitabine	es_ES
dc.subject	First-line	es_ES
dc.subject	HER-2-positive	es_ES
dc.subject	Metastatic breast cancer	es_ES
dc.title	Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer	es_ES
dc.type	journal article	es_ES
dc.identifier.doi	10.1634/theoncologist.2011-0344	es_ES
dc.identifier.idgrec	084468	es_ES